CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Fluoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03826875
NCT03826875Phase 2Completed
CompareCT.gov

Preventative Treatment of Depression in Survivors of Aneurysmal Subarachnoid Hemorrhage

University of Washington·interventional·Posted Feb 1, 2019·Updated Aug 6, 2025

In Brief

A Phase 2 clinical trial evaluating Fluoxetine and Placebo for Stroke Hemorrhagic and Depression. Completed, enrolled 8 participants across 1 site.

Detailed Summary

A double-blinded placebo-controlled randomized trial to evaluate the effect of preventative treatment of depression in survivors of aneurysmal subarachnoid hemorrhage (aSAH), a type of stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke Hemorrhagic, Depression
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 1, 2019
Enrollment StartMar 1, 2019
Primary CompletionMay 7, 2025
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 7.4 years ago

Interventions

Fluoxetinedrug

Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life

Placebodrug

Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life